Drug Profile
V 158866
Alternative Names: V-158866Latest Information Update: 05 Mar 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Neuritek Therapeutics; Vernalis
- Class Analgesics; Anxiolytics
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
- Discontinued Neuropathic pain; Pain
Most Recent Events
- 05 Mar 2021 Preclinical trials in CNS disorders in United Kingdom (PO), before March 2021 (Vernalis pipeline, March 2021)
- 13 Apr 2020 Discontinued - Phase-I for Pain in United Kingdom (PO)
- 13 Apr 2020 Discontinued - Phase-II for Neuropathic pain in USA (PO)